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n INTRODUCTION
Arboviral infections caused by dengue virus (DENV), Chikungunya virus (CHIKV) and 
Zika virus (ZIKV) are endemic in the Caribbean 
Islands, Central and South America where they 
share common vectors (Aedes mosquitoes) [1]. Al-
though DENV, CHIKV and ZIKV infections each 
have some unique characteristics, their clinical pres-
entation is usually characterized by highly similar 
febrile illnesses that may include fever, headache, 
myalgia, arthralgia, and skin rash. Consequently, 
when making a diagnosis, all three viruses should 
be screened for using appropriate tests, given that 
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sporadic cases of arbovirus co-infection (DENV/
CHIKV and DENV/CHIKV/ZIKV) have been de-
scribed in people living in endemic countries and 
returning travellers [2-5]. 
The clinical picture of arboviral infections may in-
clude signs of variably severe liver dysfunction, 
and cases suggestive of acute hepatitis due to con-
current dengue fever and hepatitis A, or hepati-
tis E viruses’ infection which have been reported 
both from India and Pakistan [6, 7]. 
Herein, we report a case of dengue infection as-
sociated with a probable hepatitis E virus (HEV) 
infection in a traveller returning from Cuba.
n CASE REPORT
A 37-year-old Cuban woman who had been living 
in Italy for five years was admitted to our Infec-
tious Disease Department in November 2018 be-
Dengue fever is a mosquito-borne infection that co-cir-
culates with Chikungunya and Zika virus infection in 
many parts of the world. Dengue virus (DENV) is occa-
sionally responsible for acute hepatitis and a few cases 
of acute hepatitis due to co-infection with DENV and 
hepatitis E virus have been described in India. A 37-year-
old Cuban woman living in Italy was admitted to our 
hospital with a presumed arboviral infection upon her 
SUMMARY
return to Italy short after a 15-day trip to her home-coun-
try to visit relatives. An acute infection due to DENV 
serotype 1 was initially diagnosed, following a clinical 
course characterized by signs of liver dysfunction that 
were possibly due to co-infection with hepatitis E virus.
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cause of a suspected arboviral infection. She had 
started complaining of high fever, chills, severe 
headache and asthenia upon her return to Italy 
from a 15-day trip to her country of origin (1-15 
November 2018) to visit friends and relatives. 
Four days after her return, a general practitioner, 
who prescribed amoxicillin-clavulanate, visited 
her. However, because symptoms persisted with 
a new onset rash on November 20, she attended 
the nearest Emergency Department, which docu-
mented fever (38.1°C) and a maculopapular rash 
involving her face, trunk and legs. Laboratory 
tests revealed leukopenia (1.65 109/L), thrombo-
cytopenia (101x109/L), increased C reactive pro-
tein values (252 mg/L) and a slight increase in 
aspartate aminotransferase (AST) levels (64 U/L). 
A chest X-ray was negative. The antibiotic ther-
apy was discontinued, and fluid hydration was 
prescribed. 
The patient was subsequently transferred to 
our ward, where she promptly underwent vari-
ous microbiological diagnostic tests for DENV, 
CHKV, and ZIKV infection. Workup included, se-
rological tests (NovaLisa Dengue virus IgM/IgG 
ELISA, NovaTec, Germany; NovaLisa Chikun-
gunya IgM/IgG ELISA, NovaTec, Germany; Zika 
virus IgM/IgG, Dia.Pro Diagnostic, Italy; Plate-
lia Dengue NS1 Ag ELISAtest, Biorad, France), 
as well as molecular testing [Multiplex real-time 
polymerase chain reaction (PCR) for DENV and 
CHKV: FTD Dengue/Chik, Fast Track Diagnostic, 
Luxenbourg; and reverse transcription PCR for 
ZKV: RealStar Zika Virus RT-PCR Altona Diag-
nostics, Germany]. Serum samples were also sent 
to the National Reference Laboratory for Arbovi-
ruses for plaque reduction neutralization testing 
(PRNT) for DENV, CHKV and ZKV [8]. 
Table 1 shows the results of the laboratory exam-
Table 1 - Laboratory test results during hospitalisation for dengue fever and hepatitis E co-infection.
Parameter Reference values
ED Hospitalisation Follow up
20/11/2018 21/11/2018
(Day 1)
23/11/2018
(Day 3)
24/11/2018
(Day 4)
25/11/2018
(day 5)
26/11/2018
(day 6)
28/11/2018
(day 8)
10/12/2018
C-reactive protein 
(mg/L)
<1.0 252 129 58 ND ND 2.2 1 0.9
Hemoglobin (g/dL) 125-155 130 120 118 122 121 123 114 110
Hematocrit (%) 38-46 39 35 35 36 36 37 34 34
RBC (1012/L) 4.13-5.15 4.83 4.44 4.35 4.57 4.53 4.62 4.23 4.05
MCV (fL) 81.8-95.3 81.6 78.7 81.0 80.0 80.4 80.0 81.0 82.7
WBC (109/L) 4.19-9.35 1.65 1.48 1.09 1.78 2.46 2.88 3.29 5.73
Neutrophils (%) 40.1-72.5 68.0 58.0 75.0 31.0 42.0 36.0 42.0 63.0
Lymphocytes (%) 19.6-46.5 19.4 24.0 17.0 52.0 41.0 46.0 37.0 25.0
Monocytes (%) 5.3-11.6 14.5 18.0 8.0 12.0 14.0 15.0 18.0 11.0
Platelets (109/L) 169-359 101 102 53 63 92 131 164 300
AST (U/L) 11-34 64 53 236 523 447 394 87 22
ALT (U/L) 8-41 31 29 114 271 286 325 184 24
PT (INR) 0.85-1.18 – 1.14 1.10 1.05 1.12 1.07 ND 1.09
aPTT (ratio) 0.85-1.20 – 1.65 1.16 1.18 0.97 0.98 ND 1.01
LDH (U/L) 125-220 320 293 583 895 635 532 292 226
Total bilirubin 
(mg/dL) 
<1.20 – 0.42 <1.20 < 1.20 < 1.20 0.65 – 1.12
Dengue IgM 
(Index)
<1 Negative
>1 Positive
– 1.9 – – – –
8.9 10.5
Dengue IgG 
(Index)
<1 Negative
>1 Positive
– 0.1 – – – –
1.4 3.1
Dengue NS1 Ag Negative – Positive – – – – – –
Dengue RNA, 
(blood)
Negative –
Positive 
(serotype 
1)
– – – – – Negative
>>> Segue
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Parameter Reference values
ED Hospitalisation Follow up
20/11/2018 21/11/2018
(Day 1)
23/11/2018
(Day 3)
24/11/2018
(Day 4)
25/11/2018
(day 5)
26/11/2018
(day 6)
28/11/2018
(day 8)
10/12/2018
Dengue RNA 
(urine)
Negative – Negative – – – – – Negative
Dengue PRNT
PRNT80* ≥10 
Positive 
PRNT50** ≥10 
Borderline
– Negative – – – – Positive –
Chikungunya IgM 
(Index)
<9 Negative
>11 Positive
–
16.92
– – – – – –
Chikungunya IgG 
(Index)
<9 Negative
>11 Positive
– 4.56 – – – – – –
Chikungunya RNA 
(blood)
Negative – Negative – – – – – –
Chikungunya RNA 
(urine)
Negative – Negative – – – – – –
Chikungunya 
PRNT
PRNT80* ≥10 
Positive 
PRNT50** ≥10 
Borderline
– Negative – – – – Negative –
Zika virus IgM 
(Index)
<0.8 Negative
>1.1 Positive
– 0.4 – – – – – –
Zika virus IgG 
(Index)
<0.8 Negative
>1.1 Positive
– 0.1 – – – – – –
Zika PRNT
PRNT80* ≥10 
Positive 
PRNT50** ≥10 
Border line
– – – – – – Negative –
HbsAg Negative – Negative – – – Negative – –
HBs Ab 
(mUI/mL)
<10 Negative
>10 Positive
– Negative – – – Negative – –
HBc IgM Negative – – – – – Negative – –
HBc IgG
<1.0 Negative
>1.0 Positive
– Negative – – – Negative – –
HCVab Negative – Negative – – – – – –
HAV IgM Negative – – – – – Negative – –
HAV IgG Negative – – – – – Positive – –
HEV IgM
<1 Negative
>1.2 Positive
– – – – – 1.4 – 1.2
HEV IgG
<0.9 Negative
>1.1 Positive
– – – – – 9.9 – 8.5
HEV RNA (blood) Negative – – – – – - – Negative
HIV 1/2 Ag-Ab Negative – Negative – – – - – –
CMV IgG 
(U/mL)
<12 Negative
>14 Positive
– – – – – 136 – –
CMV IgM 
(U/mL)
<18 Negative
>22 Positive
– – – – – 20.5 – –
CMV avidity test 
(Index) 
<0.15 low
0.15-0.25 
medium
>0.25 high
– – – – – 0.52 – –
*Serum dilution leading to an 80% reduction in viral infectious units. **Serum dilution leading to a 50% reduction in viral infectious units. 
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inations. The patient was positive for anti-DENV 
IgM, DENV- NS1 antigen, and blood RT-PCR re-
vealed the presence of DENV; she was also posi-
tive for anti-CHKV IgM, but blood and urine PCR 
were CHKV negative, and she was also negative 
for ZIKV IgG and IgM. 
PRNT for DENV and CHKV resulted negative on 
the first day of hospitalization converting posi-
tively eight days later for DENV but negative for 
CHKV.
During the first four days of hospitalization, the 
patient remained febrile, and her rash became 
generalized (face, trunk, abdomen and legs) along 
with pruritus; she also complained of nausea 
prompting administration of metoclopramide. 
Over the same period, her AST and alanine ami-
notransferase (ALT) levels increased, respectively 
reaching peaks of 523 U/L and 325 U/L. Serolog-
ical tests for viral hepatitis (A, B, C and E) and 
cytomegalovirus (CMV) were performed on the 
sixth day of hospitalization. CMV serology was 
equivocal (borderline IgM positive, IgG positive), 
but an avidity test ruled out an acute CMV infec-
tion. Serology for hepatitis A, B, C viruses was 
negative, whereas anti-hepatitis E virus (HEV) 
IgG and IgM were positive. 
The course of hospitalization was uneventful, 
and the patient was discharged after eight days 
with only slightly high liver enzyme values. A 
follow-up examination twelve days later showed 
that her liver enzyme levels had normalized; she 
was still positive for anti-HEV IgM and IgG but 
an HEV-RNA test that could only be performed at 
this time proved negative.
n DISCUSSION
We describe a case of imported dengue fever 
with acute anicteric hepatitis and probable HEV 
co-infection. An increase in liver enzyme levels is 
frequently observed during dengue fever, being 
reported in 26-85% of the cases diagnosed in en-
demic countries such as India, and in 34% of the 
cases of imported dengue [9-11]. However, the liv-
er dysfunction observed during DENV infection 
is generally mild. One study conducted in India 
found that only 11.4% of the patients with den-
gue fever had liver enzyme levels of >10 times 
above normal limits; while another study, found 
that only 13% of the patients had ALT levels >200 
IU/L [9, 10]. Nevertheless, liver failure with a 
marked increase in AST levels (up to >1000 IU/L) 
has been observed in 3.8% of the patients dying 
from dengue fever in India, and there is even one 
case report of a patient with dengue fever-related 
acute liver failure receiving a liver transplanta-
tion [10, 12]. The peak AST and ALT levels of our 
patient were respectively 15 and 8 times higher 
than normal, which is consistent with the greater 
increase in AST than in ALT described in a large 
series of patients with dengue fever [10]. 
Interestingly, in a recent retrospective study con-
ducted in Taiwan looking at over 4000 patients 
who were hospitalized with dengue fever, values 
of AST >203 UI/L, ALT >55 UI/L, AST2/ALT 
criteria >337,35 and AST/platelet count ratio in-
dex >19,18 on day 3 of illness resulted in a true 
positive rate (TPR) for identifying early mortali-
ty respectively of 90%, 78%, 100%, 100% [13]. In 
our patient, on day 3 of hospitalization, three out 
of the four mentioned variables were consistent 
with those identified with high TPR of early mor-
tality. Although the clinical picture of acute hepa-
titis presented by our patient could have been ex-
clusively attributed to dengue fever, we searched 
for other possible concomitant causes and found 
a serological pattern that was suggestive of con-
comitant acute hepatitis E. Three cases in India 
with concomitant diagnoses of dengue fever, hep-
atitis E and leptospirosis presenting with jaun-
dice, acute renal failure and encephalopathy, in 
which the diagnosis of HEV infection was based 
on a single positive anti-HEV IgM test have been 
reported in the literature to date [6, 14, 15].
However, according to the guidelines of the 
European Association for the Study of the Liv-
er (EASL), HEV RNA testing (alone or together 
with IgM and IgG testing) is recommended to 
ensure an accurate diagnosis of hepatitis E, al-
though it is worth noting that HEV-RNA can be 
detected only in 25-44% of patients with acute 
hepatitis, even when it is sought early in the 
course of infection [16-18]. In our case, we fol-
lowed an algorithm in which HEV-RNA in blood 
and stools are required to confirm a positive an-
ti-HEV IgM serological test. Unfortunately, our 
patient had already been discharged when the 
results of the anti-HEV antibody test became 
available, and this prevented us from immedi-
ately searching for HEV-RNA. The duration of 
HEV-RNA in blood and stools is very short dur-
ing the symptomatic phase of hepatitis E, which 
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may explain the negative result of the HEV-RNA 
test that could only be performed several days 
after the onset of acute hepatitis. We conclude 
that the prompt use of both serological and mo-
lecular methods would have allowed a more ac-
curate diagnosis of HEV infection. 
Finally, the finding that our patient was positive 
for anti-CHIKV IgM further confirms the exist-
ence of previously described serological cross-re-
actions between Flaviviruses (DENV, ZIKV) and 
between them and Alphavirus (CHIKV) that can 
complicate the interpretation of serological tests 
[8, 19-22]. Molecular tests are highly sensitive 
and specific for Arboviruses, and allow the spe-
cific agent involved to be identified. In our case, 
the prompt use of RT-PCR solved the question of 
serological cross-reactions between DENV and 
CHIKV by indicating DENV as the cause of the 
patient’s infection. However, it should be con-
sidered that the short duration of viremia during 
acute arboviral infection is a limitation of molecu-
lar tests, whereas PRNT (which allows virus-spe-
cific neutralizing antibodies to be measured) has 
proved to be highly specific in identifying the 
agents involved in primary arboviral infections. 
Studies suggest that this test should be included 
in the routine diagnostic algorithm of arboviral 
infections, especially in the case of patients pre-
senting some time after the acute onset of symp-
toms [8, 22].
In conclusion, although arboviral infections are 
frequently associated with some degree of liv-
er dysfunction, careful consideration should al-
ways be given to the possible contribution of liver 
damage caused by co-infection with the various 
agents that are prevalent in areas in which arbovi-
ruses are endemic. 
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